Osdoit M, Yau C, W Symmans F, Boughey JC, Ewing CA, Balassanian R, Chen Y-Y, Krings G, Wallace AM, Zare S, et al. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 ;157(11):1034-1041.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy A-S, Laé M, Reyal F, Sonke GS, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 ;23(1):149-160.
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen Y-Y, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, et al. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 ;33(8):814-823.
